Fundz
Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Ascendis Pharma and Novo Nordisk Finalize Exclusive Collaboration Agreement

Dec 18, 2024•over 1 year ago

Contract Type

partnership

BiotechnologyPharmaceuticalBiopharma

Description

The collaboration agreement between Ascendis Pharma and Novo Nordisk has reached a significant milestone with the expiration of the regulatory waiting period. Novo Nordisk has been granted an exclusive license to develop and market products targeting obesity and type 2 diabetes using Ascendis Pharma's TransCon technology in metabolic and cardiovascular diseases. As part of this collaboration, Ascendis Pharma is set to receive a $100 million milestone payment.

Company Information

Company

Ascendis Pharma A/S and Royalty Pharma plc

About

Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, while Royalty Pharma plc is a leading funder of innovation across the biopharma industry based in New York.

Predictive Intelligence
Strategic

ML-powered predictions for Ascendis Pharma A/S and Royalty Pharma plc's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.